INT293491

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.87
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.06
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Erbb2) plasma membrane (Erbb2) nucleus (Erbb2)
kinase activity (Erbb2) cytoplasm (Erbb2)
Erbb2 (Mus musculus)
Pain Link Frequency Relevance Heat
imagery 18 5.00 Very Low Very Low Very Low
isoflurane 4 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
positron emission tomography 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 116 95.04 Very High Very High Very High
Breast Cancer 6 5.00 Very Low Very Low Very Low
Apoptosis 4 5.00 Very Low Very Low Very Low
Hyperplasia 2 5.00 Very Low Very Low Very Low
Disease 2 5.00 Very Low Very Low Very Low
Aggression 2 5.00 Very Low Very Low Very Low
Shock 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The data confirm that PU-H71 degrades HER2/neu levels to ?
Protein_catabolism (degrades) of HER2/neu
1) Confidence 0.87 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810330 Disease Relevance 0.52 Pain Relevance 0
The 89Zr-DFO-trastuzumab biodistribution data suggest that a single-dose of PU-H71 induces a sustained effect in terms of HER2/neu and other client oncoprotein degradation for at least 48 h post-administration.
Protein_catabolism (degradation) of HER2/neu
2) Confidence 0.87 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810330 Disease Relevance 0.55 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox